MKI67 and neoplasm: More importantly, patients with both EGFR mutations and amplifications exhibited higher values of the clinical detected tumor proliferative index (evaluated by Ki67 percentage of positive nuclei) (Fig. 3G, Supplementary Fig. 6G).